TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00588536
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
Study: NCT00588536
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
Study: NCT06416735
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
Study: NCT04541433
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9833 taken orally
Study: NCT02036528
Drug: Gentamicin Topical Gel
Normalized name: gentamicin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02036528
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003061
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01308983
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 10 mg orally once a day for 16 weeks
Study: NCT03016533
Drug: ABC/DTG/3TC immediate release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
Study: NCT04459767
Drug: Vupanorsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg subcutaneous injection
Study: NCT04459767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT00268151
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00054171
Drug: aminolevulinic acid hydrochloride
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01000545
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 soft-gel capsules per day to be taken orally for 12 months
Study: NCT00871598
Drug: BTT1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, three infusions over three weeks
Study: NCT00871598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous, three infusions over three weeks
Study: NCT00871598
Drug: BTT1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test challenge
Study: NCT03424005
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
Study: NCT01318733
Drug: CD07805/47 gel 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
Study: NCT03503227
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
Study: NCT00082927
Drug: ibandronate sodium
Normalized name: Ibandronate Sodium
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179775
Drug: Quince's oxymel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02179775
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00448682
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01208831
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03957590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match tislelizumab
Study: NCT02017600
Drug: ND-420
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-420 50 mg/m2 on day1
Study: NCT02017600
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil 700 mg/m2 daily, day1 to day4
Study: NCT02650648
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight\<70kg) or 1500mg/m\^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
Study: NCT00802529
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
Study: NCT02604017
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT02195687
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
Study: NCT01117051
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00673270
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg of intravenous hydrocortisone
Study: NCT00673270
Drug: Placebo of Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of isotonic saline solution
Study: NCT02545231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
Study: NCT03280927
Drug: Jublia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jublia® topical solution
Study: NCT00882401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo at same dose schedule as ergocalciferol
Study: NCT01757366
Drug: First-line Chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Study: NCT01751802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Ecopipam
Study: NCT01369355
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT02436096
Drug: TNX-102 SL Tablet, 2.8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Study: NCT02436096
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
Study: NCT02319759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
Study: NCT02187848
Drug: SAR408701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
Study: NCT00024167
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 IV, day 1 on Weeks 1, 3, 5
Study: NCT01936909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01721577
Drug: AXL1717
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-1 receptor inhibitor
Study: NCT01536288
Drug: Rhodiola crenulata
Normalized name: RHODIOLA CRENULATA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Study: NCT01536288
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
Study: NCT03577171
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 300mg QD of ABI-H0731 tablets orally.
Study: NCT03577171
Drug: SOC ETV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SOC ETV (0.5 mg QD) orally as per approved package insert.
Study: NCT03577171
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching QD placebo tablets orally.
Study: NCT04577352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per schedule specified in the arm.
Study: NCT03209830
Drug: OSU 6162
Normalized name: Osurnia
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Study: NCT00408005
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00408005
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00408005
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03209830
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Study: NCT01410695
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01410695
Drug: Placebo (methotrexate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01410695
Drug: Placebo (masitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00240084
Drug: nesiritide (Natrecor(TM))
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of IV nesiritide
Study: NCT01327638
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with SpA/AS who took etoricoxib
Study: NCT00408005
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00408005
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or PO
Study: NCT01327638
Drug: nsNSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with SpA/AS who took nsNSAIDs
Study: NCT00969059
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
Study: NCT01281878
Drug: Vitamin B 6
Normalized name: vitamin B 6 100 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
Study: NCT03479671
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
Study: NCT00304954
Drug: Oral Rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
Study: NCT02626182
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill that looks like sildenafil tablets
Study: NCT03578276
Drug: Prednisolone acetate 1% ophthalmic suspension
Normalized name: Prednisolone Acetate 1% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal anti-inflammatory
Study: NCT03578276
Drug: Bromfenac 0.075% Oph Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory
Study: NCT01911637
Drug: VBY-036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug VBY-036
Study: NCT01911637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01406873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
Study: NCT00781131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactulose placebo
Study: NCT01907724
Drug: IDX719
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX719 will be supplied as a 50 mg tablet for oral administration.
Study: NCT01907724
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC647055 will be supplied as 150 mg capsules for oral administration.
Study: NCT00350519
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive standard of care based on the Institution's treatment policy.
Study: NCT01676584
Drug: RO6811135
Approvals — FDA: no, EMA: no, PMDA: no
Description: single ascending doses sc
Study: NCT01676584
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single doses sc
Study: NCT00478361
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 40 mg/m\^2 IV over 20 minutes
Study: NCT03066440
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Study: NCT02649608
Drug: 0.04 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg dose group
Study: NCT02649608
Drug: 0.2 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg dose group
Study: NCT02649608
Drug: 0.4 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg dose group
Study: NCT02649608
Drug: 0.6 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg dose group
Study: NCT02649608
Drug: 0.8 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg dose group
Study: NCT02649608
Drug: 1.0 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg dose group
Study: NCT02649608
Drug: 1.2 mg Lu AE04621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg dose group
Study: NCT02883049
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02883049
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02883049
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT02883049
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT04602390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT02883049
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02883049
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and IV
Study: NCT03379675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Study: NCT00744211
Drug: 1mg/kg sitaxsentan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
Study: NCT02008656
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02008656
Drug: Capecitabine (Xeloda®)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04488107
Drug: FCN-437c
Approvals — FDA: no, EMA: no, PMDA: no
Description: - FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
Study: NCT03639571
Drug: Ibuprofen 200 mg TEPI Medicated Plaster
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
Study: NCT04433143
Drug: Minocycline hydrochloride capsules were taken orally
Normalized name: minocycline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumenis OneTM, OPT tender system produced by American Medical Science Company; Use four of the filters. Acne filter has a wavelength of 400-600/800-1200nm. Three pulses were used for treatment, with a pulse width of 5.0ms, a pulse delay of 30ns, and an energy density of 15j /cm2. The instrument parameters were selected according to the skin lesion characteristics, age and tolerance.
Study: NCT03512639
Drug: Homeopathic Medication
Normalized name: homeopathic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
Study: NCT03512639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
Study: NCT01219049
Drug: Tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg / day
Study: NCT01219049
Drug: Tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2000 mg / day
Study: NCT01219049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily
Study: NCT02235961
Drug: NNC9204-0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Study: NCT02235961
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as single subcutaneous (s.c., under the skin) injections.
Study: NCT02375724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
Study: NCT00227344
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
Study: NCT04152655
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets three times a day
Study: NCT00429468
Drug: Vicodin® CR (extended-release hydrocodone/acetaminophen)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603159
Drug: Capecitabine(Aibin)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
Study: NCT04325035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
Study: NCT04475939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered
Study: NCT02749032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
Study: NCT00822809
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg premedication
Study: NCT03878472
Drug: SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
Study: NCT00986154
Drug: low molecular weight heparin/unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
Study: NCT04637828
Drug: GNS561
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug
Study: NCT00876798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
Study: NCT01923168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (of BYL719 or BKM120) + Letrozole
Study: NCT02764125
Drug: levodopa MR
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa MR/carbidopa/ODM-104
Study: NCT03706898
Drug: Elpida®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elpida® capsules, 20mg
Study: NCT04314310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equal volume of normal saline
Study: NCT02567435
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and PO